Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia.
Epilepsia Open. 2023 Sep;8(3):1123-1132. doi: 10.1002/epi4.12792. Epub 2023 Jul 28.
Up to 70% of people living with epilepsy could become seizure-free with the appropriate use of antiseizure medicines. However, three quarters of people with epilepsy living in low-income countries do not get the treatment they need and also do not access antiseizure medicines. The purpose of this study was to assess the availability, price, and affordability of antiseizure medicines in Addis Ababa, Ethiopia.
A cross-sectional study was done in selected pharmacies using a questioner developed after the modification of World Health Organization/Health Action International methodology. Data on the availability and price of lowest-priced generics and originator brand antiseizure medicines from essential medicines list in Ethiopia were collected from seven public sectors, five private sectors, and seven other sectors (five Kenema Public Community and two Red Cross Pharmacies) in Addis Ababa between 09 May and 31 2022. The data were analyzed using the modified World Health Organization/Health Action International workbook part I excel sheet. Descriptive results were reported in text and table format.
The overall availability of lowest-priced generics medication was 52%. The availability of lowest-priced generics was 62.86%, 30%, 55%, and 50% in public, private, Red Cross, and Kenema Public Community Pharmacies, respectively. The median price ratio in the public, private, Red Cross, and Kenema Public Community Pharmacy was 1.45, 3.72, 1.46, and 1.7, respectively. All the medications were unaffordable. Patients may be required to pay more than 6-month wage to purchase standard treatment for 1 month only.
The overall availability of antiseizure medicines was lower than the WHO target for noncommunicable diseases. All the available medicines were unaffordable.
在适当使用抗癫痫药物的情况下,高达 70%的癫痫患者可以实现无癫痫发作。然而,四分之三生活在低收入国家的癫痫患者没有得到他们所需的治疗,也无法获得抗癫痫药物。本研究旨在评估埃塞俄比亚亚的斯亚贝巴抗癫痫药物的可及性、价格和可负担性。
在选定的药店进行了一项横断面研究,使用的问卷是在世界卫生组织/国际健康行动方法修改后制定的。从埃塞俄比亚基本药物清单中收集了来自七个公共部门、五个私营部门和七个其他部门(五个凯内马公共社区和两个红十字会药房)的最低价仿制药和原研品牌抗癫痫药物的供应和价格数据。这些数据在 2022 年 5 月 9 日至 31 日期间在亚的斯亚贝巴进行了分析,使用了修改后的世界卫生组织/国际健康行动国际工作簿第一部分 Excel 工作表。结果以文字和表格形式报告。
最低价仿制药的总体可得性为 52%。最低价仿制药的可得性分别为 62.86%、30%、55%和 50%,在公共、私人、红十字会和凯内马公共社区药房。公共、私人、红十字会和凯内马公共社区药房的中位数价格比分别为 1.45、3.72、1.46 和 1.7。所有药物都无法负担得起。患者可能需要支付超过 6 个月的工资才能购买仅 1 个月的标准治疗。
抗癫痫药物的总体可得性低于世界卫生组织针对非传染性疾病的目标。所有可用的药物都无法负担得起。